ArticleOncotarget2017
Cancer killers in the human gut microbiota: diverse phylogeny and broad spectra.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Quxie Capsule Modulating Gut Microbiome and Its Association With T cell Regulation in Patients With Metastatic Colorectal Cancer: Result From a Randomized Controlled Clinical Trial.Integrative cancer therapiesTrial
- Article
- Dysbiosis and extraintestinal cancers.Journal of experimental & clinical cancer research : CR · 2025Review
- Current Advances of Nanomaterial-Based Oral Drug Delivery for Colorectal Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2024Review
- Role of the gut microbiota in hematologic cancer.Frontiers in microbiology · 2023Review
- The gut microbiota correlate with the disease characteristics and immune status of patients with untreated diffuse large B-cell lymphoma.Frontiers in immunology · 2023Article
- Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes.International journal of molecular sciences · 2022Article
- Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review.Frontiers in pharmacology · 2022Review
- Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients.American journal of cancer research · 2022Article
- Review
- Prodigiosin ofMolecules (Basel, Switzerland) · 2021Article
- Review
- A Comparison Study of Age and Colorectal Cancer-Related Gut Bacteria.Frontiers in cellular and infection microbiology · 2021Article
- Dissection of the Functional Mechanism of Human Gut Bacterial Strain AD16 by Secondary Metabolites' Identification, Network Pharmacology, and Experimental Validation.Frontiers in pharmacology · 2021Article
- Novel Bacillus strains from the human gut exert anticancer effects on a broad range of malignancy types.Investigational new drugs · 2020Article
- Designing Aptamer-Gold Nanoparticle-Loaded pH-Sensitive Liposomes Encapsulate Morin for Treating Cancer.Nanoscale research letters · 2020Article
- The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View.Trends in cancer · 2020Review
- Functional Genomics Insights Into the Pathogenicity, Habitat Fitness, and Mechanisms Modifying Plant Development ofFrontiers in microbiology · 2020Article
- Dysbiosis of the Gut Microbiome in Lung Cancer.Frontiers in cellular and infection microbiology · 2019Article
- Microbiome as a Target for Cancer Therapy.Integrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer as a large group of complex diseases is believed to result from the interactions of numerous genetic and environmental factors but may develop in people without any known genetic or environmental risks, suggesting the existence of other powerful factors to influence the carcinogenesis process. Much attention has been focused recently on particular members of the intestinal microbiota for their potential roles in promoting carcinogenesis. Here we report the identification and characterization of intestinal bacteria that exhibited potent anti-malignancy activities on a broad range of solid cancers and leukemia. We collected fecal specimens from healthy individuals of different age groups (preschool children and university students), inspected their effects on cancer cells, and obtained bacteria with potent anti-malignancy activities. The bacteria mostly belonged to Actinobacteria but also included lineages of other phyla such as Proteobacteria and Firmicutes. In animal cancer models, sterile culture supernatant from the bacteria highly effectively inhibited tumor growth. Remarkably, intra-tumor administration of the bacterial products prevented metastasis and even cleared cancer cells at remote locations from the tumor site. This work demonstrates the prevalent existence of potent malignancy-killers in the human intestinal microbiota, which may routinely clear malignant cells from the body before they form cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.